HHM Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

HHM Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-260	Closed	-$31.1K	–	820
2022 Q4	$31.1K	Hold	260	–	–	0.01%	305
2022 Q3	$28K	Hold	260	–	–	0.01%	307
2022 Q2	$25K	Hold	260	–	–	0.01%	392
2022 Q1	$24K	Hold	260	–	–	0.01%	416
2021 Q4	$22K	Hold	260	–	–	0.01%	414
2021 Q3	$25K	Hold	260	–	–	0.01%	385
2021 Q2	$25K	Hold	260	–	–	0.01%	372
2021 Q1	$25K	Hold	260	–	–	0.01%	351
2020 Q4	$25K	Hold	260	–	–	0.01%	333
2020 Q3	$25K	Hold	260	–	–	0.01%	297
2020 Q2	$32K	Hold	260	–	–	0.01%	265
2020 Q1	$23K	Buy	+260	New	+$25.4K	0.01%	286

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HHM Wealth Advisors's NBIX Position: Q1 2023 in Review

HHM Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 260 shares — an estimated $31.1K sold.

HHM Wealth Advisors first reported a position in NBIX in Q1 2020 and held it in 12 quarters. The position peaked at $32K in Q2 2020. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

HHM Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
HHM Wealth Advisors sold 260 Neurocrine Biosciences shares in Q1 2023, an estimated $31.1K.
HHM Wealth Advisors first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 12 quarters.
HHM Wealth Advisors's Neurocrine Biosciences position peaked at $32K in Q2 2020.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on HHM Wealth Advisors's 13F filing for Q1 2023, filed 2 May 2023.